Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324. https://doi.org/10.1158/1078-0432.Ccr-05-1634

Article  PubMed  CAS  Google Scholar 

Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Rhiem K, Schmitt WD, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G, Loibl S (2019) NAB-Paclitaxel improves Disease-Free Survival in early breast Cancer: GBG 69-GeparSepto. J Clin Oncol 37(25):2226–2234. https://doi.org/10.1200/jco.18.01842

Article  PubMed  CAS  Google Scholar 

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-negative breast Cancer. N Engl J Med 379(22):2108–2121. https://doi.org/10.1056/NEJMoa1809615

Article  PubMed  CAS  Google Scholar 

Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356. https://doi.org/10.1016/s1470-2045(15)00542-2

Article  PubMed  CAS  Google Scholar 

Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 11(11):4136–4143. https://doi.org/10.1158/1078-0432.Ccr-04-2291

Article  PubMed  CAS  Google Scholar 

Gradishar WJ (2006) Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7(8):1041–1053. https://doi.org/10.1517/14656566.7.8.1041

Article  PubMed  CAS  Google Scholar 

Yardley DA (2013) Nab-Paclitaxel mechanisms of action and delivery. J Control Release 170(3):365–372. https://doi.org/10.1016/j.jconrel.2013.05.041

Article  PubMed  CAS  Google Scholar 

Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Multiple-pool cell lifespan models for neutropenia to assess the population pharmacodynamics of unbound paclitaxel from two formulations in cancer patients. Cancer Chemother Pharmacol 63(6):1035–1048. https://doi.org/10.1007/s00280-008-0828-1

Article  PubMed  CAS  Google Scholar 

Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A (2002) Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol 20(2):574–581. https://doi.org/10.1200/jco.2002.20.2.574

Article  PubMed  CAS  Google Scholar 

Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803. https://doi.org/10.1200/jco.2005.04.937

Article  PubMed  CAS  Google Scholar 

Hurria A, Blanchard MS, Synold TW, Mortimer J, Chung CT, Luu T, Katheria V, Rotter AJ, Wong C, Choi A, Feng T, Ramani R, Doan CM, Brown J, Somlo G (2015) Age-related changes in nanoparticle albumin-bound paclitaxel pharmacokinetics and pharmacodynamics: influence of chronological versus functional age. Oncologist 20(1):37–44. https://doi.org/10.1634/theoncologist.2014-0202

Article  PubMed  CAS  Google Scholar 

Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019–6026. https://doi.org/10.1200/jco.2005.11.013

Article  PubMed  CAS  Google Scholar 

Lu H, Zha S, Zhang W, Wang Q, Jiang D, Xu X, Zheng X, Qiu M, Shan C (2021) A systematic review and meta-analysis of nab-paclitaxel mono-chemotherapy for metastatic breast cancer. BMC Cancer 21(1):830. https://doi.org/10.1186/s12885-021-08441-z

Article  PubMed  PubMed Central  CAS  Google Scholar 

Munster PN, Greenstein AE, Fleming GF, Borazanci E, Sharma MR, Custodio JM, Tudor IC, Pashova HI, Shepherd SP, Grauer A, Sachdev JC (2022) Overcoming Taxane Resistance: preclinical and phase 1 studies of Relacorilant, a selective glucocorticoid receptor modulator, with Nab-Paclitaxel in solid tumors. Clin Cancer Res 28(15):3214–3224. https://doi.org/10.1158/1078-0432.Ccr-21-4363

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S (2014) Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol 54(10):1097–1107. https://doi.org/10.1002/jcph.304

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tsushima T, Kasai H, Tanigawara Y (2020) Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer. Cancer Chemother Pharmacol 86(4):487–495. https://doi.org/10.1007/s00280-020-04140-x

Article  PubMed  CAS  Google Scholar 

Campbell K, Chadha N, Dimri S, Wang W, Li E (2022) G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Expert Rev Hematol 15(7):619–633. https://doi.org/10.1080/17474086.2022.2093712

Article  PubMed  CAS  Google Scholar 

Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50(5):295–306. https://doi.org/10.2165/11586040-000000000-00000

Article  PubMed  CAS  Google Scholar 

Stern ST, Martinez MN, Stevens DM (2016) When is it important to measure unbound drug in evaluating Nanomedicine Pharmacokinetics? Drug Metab Dispos 44(12):1934–1939. https://doi.org/10.1124/dmd.116.073148

Article  PubMed  PubMed Central  CAS  Google Scholar 

Xiong Y, Xie L, Tang L, Xiao D, Shi W, Wang Y, Li Y, Han X, Ying X, Zheng Y (2023) A liposomal etoposide with a sustained drug release effectively alleviated the therapy-related leukemia. Int J Pharm 646:123437. https://doi.org/10.1016/j.ijpharm.2023.123437

Article  PubMed  CAS  Google Scholar 

Henningsson A, Karlsson MO, Viganò L, Gianni L, Verweij J, Sparreboom A (2001) Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 19(20):4065–4073. https://doi.org/10.1200/jco.2001.19.20.4065

Article  PubMed  CAS  Google Scholar 

Henningsson A, Sparreboom A, Sandström M, Freijs A, Larsson R, Bergh J, Nygren P, Karlsson MO (2003) Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients. Eur J Cancer 39(8):1105–1114. https://doi.org/10.1016/s0959-8049(03)00126-6

Article  PubMed  CAS  Google Scholar 

Bulitta JB, Zhao P, Arnold RD, Kessler DR, Daifuku R, Pratt J, Luciano G, Hanauske AR, Gelderblom H, Awada A, Jusko WJ (2009) Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus taxol in cancer patients. Cancer Chemother Pharmacol 63(6):1049–1063. https://doi.org/10.1007/s00280-008-0827-2

Article  PubMed  CAS  Google Scholar 

Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14(13):4200–4205. https://doi.org/10.1158/1078-0432.Ccr-07-4592

Article  PubMed  PubMed Central  CAS  Google Scholar 

Malhi S, Stesco N, Alrushaid S, Lakowski TM, Davies NM, Gu X (2017) Simultaneous quantification of reparixin and paclitaxel in plasma and urine using ultra performance liquid chromatography-tandem mass spectroscopy (UHPLC-MS/MS): application to a preclinical pharmacokinetic study in rats. J Chromatogr B Analyt Technol Biomed Life Sci 1046:165–171. https://doi.org/10.1016/j.jchromb.2016.12.015